ONCrg is heading to WCLC 2026!
Our team will be tracking the latest breakthroughs and clinical updates shaping thoracic oncology.
Planning your conference coverage or need strategic intelligence from WCLC? Start with our ONCrg planner.
ONCrg is anticipating:
• Data on novel therapies in NSCLC patient subsets with high unmet need:
• First Phase III data for zipalertinib in 1L EGFR ex20ins+ NSCLC
• Potentially registrational data for zidesamtinib in TKI-naive ROS1+ NSCLC
• Competing abstracts with first CN Phase III data for two different B7-H3 ADCs in relapsed SCLC:
• Medlink/Roche’s tambotatug pelitecan
• Jiangsu Hansoh/GSK’s risvutatug rezetecan
Click here for more details about ONCrg Conference Coverage.
- Oncology Insights
- NSCLC
- SCLC
- WCLC 2026
- Clinical Trials
- +2